Comparison of visuospatial and verbal abilitiesin first psychotic episode of schizophrenia spectrum comparison of visuospatial and verbal abilities in first psychotic episode of schizophrenia spectrum disorder: Impact on global functioning and quality of life

Frontiers in Behavioral Neuroscience

Volumn 9, Issue DEC, 2015, Pages

  Rodriguez, Mabel ^a   Spaniel, Filip ^a,b   Konradova, Lucie ^a   Sedlakova, Katerina ^a,b   Dvorska, Karolina ^b   Prajsova, Jitka ^a   Kratochvilova, Zuzana ^a   Levcik, David ^c   Vlcek, Kamil ^a,c   Fajnerova, Iveta ^a,b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Antipsychotic medication; Cognitive deficit; First psychotic episode; Global functioning; Quality of life; Schizophrenia spectrum disorder; Verbal functions; Visuospatial functions

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPTH PERCEPTION; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HUMAN; LEARNING; MALE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; TREATMENT OUTCOME;

EID: 84957580884     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2015.00322     Document Type: Article

References (88)

1. Addington, J., Addington, D., and Maticka-Tyndale, E. (1991). Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr. Res. 5, 123–134. doi:10.1016/0920-9964(91)90039-T.
2. Aksaray, G., Oflu, S., Kaptanoglu, C., and Bal, C. (2002). Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 1217–1219. doi:10.1016/S0278-5846(02)00217-8.
3. Andreasen, N. C., Carpenter, W. T. Jr., Kane, J. M., Lasser, R. A., Marder, S. R., and Weinberger, D. R. (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441–449. doi:10.1176/appi.ajp.162.3.441.
4. Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D., and Ho, B. C. (2010). Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 67, 255–262. doi:10.1016/j.biopsych.2009.08.040.
5. Arana, G. W. (2000). An overview of side effects caused by typical antipsychotics. J. Clin. Psychiatry 61(Suppl. 8), 5–11. Available online at:http://www.psychiatrist.com/JCP/article/Pages/2000/v61s08/v61s08002a.aspx.
6. Bilder, R. M., Goldman, R. S., Robinson, D., Reiter, G., Bell, L., Bates, J. A., et al. (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157, 549–559. doi:10.1176/appi.ajp.157.4.549.
7. Bilder, R. M., Turkel, E., Lipschutz-Broch, L., and Lieberman, J. A. (1992). Antipsychotic medication effects on neuropsychological functions. Psychopharmacol. Bull. 28, 353–366.
8. Bowie, C. R., Twamley, E. W., Anderson, H., Halpern, B., Patterson, T. L., and Harvey, P. D. (2007). Self-assessment of functional status in schizophrenia. J. Psychiatr. Res. 41, 1012–1018. doi:10.1016/j.jpsychires.2006.08.003.
9. Bubeníková, V., Votava, M., Horáček, J., Páleníček, T., and Dockery, C. (2005). The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol. Biochem. Behav. 80, 591–596. doi:10.1016/j.pbb.2005.01.012.
10. Butler, P. D., Zemon, V., Schechter, I., Saperstein, A. M., Hoptman, M. J., Lim, K. O., et al. (2005). Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch. Gen. Psychiatry 62, 495–504. doi:10.1001/archpsyc.62.5.495.
11. Černochová, D., Goldmann, P., Král, P., Soukupová, T., Šnorek, P., and Havlůj, V. (2010). Wechslerova Inteligenční škála Pro Dospělé WAIS-III. Praha: Hogrefe-Test Centrum.
12. Chaplin, R., Barley, M., Cooper, S. J., Kusel, Y., McKendrick, J., Stephenson, D., et al. (2006). The impact of intellectual functioning on symptoms and service use in schizophrenia. J. Intellect. Disabil. Res. 50, 288–294. doi:10.1111/j.1365-2788.2006.00837.x.
13. Cocchi, L., Bosisio, F., Berchtold, A., Orita, A., Debbané, M., Wood, S. J., et al. (2009). Visuospatial encoding deficits and compensatory strategies in schizophrenia revealed by eye movement analysis during a working memory task. Acta Neuropsychiatr. 21, 75–83. doi:10.1111/j.1601-5215.2009.00369.x.
14. Cummings, J. L., and Mega, M. S. (2003). “Visuospatial, visuoperceptual, and right hemisphere disturbances,” in Neuropsychiatry and Behavioral Neuroscience, eds J. L. Cummings and M. S. Mega (NewYork, NY: Oxford University Press), 114–127.
15. de Vignemont, F., Zalla, T., Posada, A., Louvegnez, A., Koenig, O., Georgieff, N., et al. (2006). Mental rotation in schizophrenia. Conscious. Cogn. 15, 295–309. doi:10.1016/j.concog.2005.08.001.
16. Dinges, D. F., Orne, M. T., and Orne, E. C. (1985). Assessing performance upon abrupt awakening from naps during quasi-continuous operations. Behav. Res. Methods Instrum. Comput. 17, 37–45. doi:10.3758/BF03200895.
17. Doniger, G. M., Silipo, G., Rabinowicz, E. F., Snodgrass, J. G., and Javitt, D. C. (2001). Impaired sensory processing as a basis for object-recognition deficits in schizophrenia. Am. J. Psychiatry 158, 1818–1826. doi:10.1176/appi.ajp.158.11.1818.
18. Dragomirecká, E., and Bartoňová, J. (2006a). Dotazník kvality života Světové zdravotnické organizace WHOQOL-BREF: Psychometrické vlastnosti a první zkušenosti s českou verzí (The World Health Organization quality of life assessment WHOQOL_BREF. Psychometric properties and first experience with czech version). Psychiatrie 10, 144–149. Available online at: http://www.tigis.cz/images/stories/psychiatrie/2006/03/02_dragomirec_psych_3-06.pdf.
19. Dragomirecká, E., and Bartoňová, J. (2006b). WHOQOL-BREF, WHOQOL-100: World Health Organization Quality of Life Assessment: příručka pro uživatele české verze dotazníků kvality života Světové zdravotnické organizace. Praha: Psychiatrické centrum Praha.
20. Eack, S. M., and Newhill, C. E. (2007). Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr. Bull. 33, 1225–1237. doi:10.1093/schbul/sbl071.
21. Evans, J. J., Chua, S. E., McKenna, P. J., and Wilson, B. A. (1997). Assessment of the dysexecutive syndrome in schizophrenia. Psychol. Med. 27, 635–646. doi:10.1017/S0033291797004790.
22. Fajnerová, I., Rodriguez, M., Levčík, D., Konrádová, L., Mikoláš, P., Brom, C., et al. (2014). A virtual reality task based on animal research-spatial learning and memory in patients after the first episode of schizophrenia. Front. Behav. Neurosci. 8:157. doi:10.3389/fnbeh.2014.00157.
23. Fiszdon, J. M., Choi, J., Goulet, J., and Bell, M. D. (2008). Temporal relationship between change in cognition and change in functioning in schizophrenia. Schizophr. Res. 105, 105–113. doi:10.1016/j.schres.2008.06.010.
24. Fioravanti, M., Carlone, O., Vitale, B., Cinti, M. E., and Clare, L. (2005). A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol. Rev. 15, 73–95. doi:10.1007/s11065-005-6254-9.
25. Folley, B. S., Astur, R., Jagannathan, K., Calhoun, V. D., and Pearlson, G. D. (2010). Anomalous neural circuit function in schizophrenia during a virtual Morris water task. Neuroimage 49, 3373–3384. doi:10.1016/j.neuroimage.2009.11.034.
26. Gaite, L., Vázquez-Barquero, J. L., Herrán, A., Thornicroft, G., Becker, T., Sierra-Biddle, D., et al. (2005). Main determinants of global assessment of functioning score in schizophrenia: a European multicenter study. Compr. Psychiatry 46, 440–446. doi:10.1016/j.comppsych.2005.03.006.
27. Golden, C. J., Espe-Pfeifer, P., and Wachsler-Felder, J. (2002). Neuropsychological Interpretation of Objective Psychological Tests. Fort Lauderdale, FL: Kluwer Academic Publishers; Nova Southeastern University.
28. Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., et al. (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56, 301–307. doi:10.1016/j.biopsych.2004.06.023.
29. Hanlon, F. M., Weisend, M. P., Hamilton, D. A., Jones, A. P., Thoma, R. J., Huang, M., et al. (2006). Impairment on the hippocampal-dependent virtual Morris water task in schizophrenia. Schizophr. Res. 87, 67–80. doi:10.1016/j.schres.2006.05.021.
30. Harvey, P. D., Sabbag, S., Prestia, D., Durand, D., Twamley, E. W., and Patterson, T. L. (2012). Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J. Psychiat. Res. 46, 1546–1552. doi:10.1016/j.jpsychires.2012.08.018.
31. Heinrichs, R. W., and Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426–445. doi:10.1037/0894-4105.12.3.426.
32. Heslegrave, R. J., Awad, A. G., and Voruganti, L. N. (1997). The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J. Psychiatry Neurosci. 22, 235–243.
33. Houthoofd, S. A., Morrens, M., and Sabbe, B. G. (2008). Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin. Ther. 30, 1565–1589. doi:10.1016/j.clinthera.2008.09.014.
34. Ihara, H., Berrios, G. E., and McKenna, P. J. (2003). The association between negative and dysexecutive syndromes in schizophrenia: a cross-cultural study. Behav. Neurol. 14, 63–74. doi:10.1155/2003/304095.
35. Jones, P. B., Barnes, T. R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., et al. (2006). Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63, 1079–1087. doi:10.1001/archpsyc.63.10.1079.
36. Jones, S. H., Thornicroft, G., Coffey, M., and Dunn, G. (1995). A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 166, 654–659. doi:10.1192/bjp.166.5.654.
37. Kay, S. R., Fiszbein, A., and Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276. doi:10.1093/schbul/13.2.261.
38. Keefe, R. S., Bilder, R. M., Davis, S. M., Harvey, P. D., Palmer, B. W., Gold, J. M., et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633–647. doi:10.1001/archpsyc.64.6.633.
39. Keefe, R. S., and Fenton, W. S. (2007). How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr. Bull. 33, 912–920. doi:10.1093/schbul/sbm046.
40. Kessels, R. P., van Zandvoort, M. J., Postma, A., Kappelle, L. J., and de Haan, E. H. (2000). The corsi block-tapping task: standardization and normative data. Appl. Neuropsychol. 7, 252–258. doi:10.1207/S15324826AN0704_8.
41. Khan, A., Yavorsky, W. C., Liechti, S., DiClemente, G., Rothman, B., Opler, M., et al. (2013). Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the positive and negative syndrome scale (PANSS). J. Clin. Psychopharmacol. 33, 109–117. doi:10.1097/JCP.0b013e3182776ebe.
42. Landgraf, S., Krebs, M. O., Olié, J. P., Committeri, G., van der Meer, E., Berthoz, A., et al. (2010). Real world referencing and schizophrenia: are we experiencing the same reality? Neuropsychologia 48, 2922–2930. doi:10.1016/j.neuropsychologia.2010.05.034.
43. Leeson, V. C., Barnes, T. R., Hutton, S. B., Ron, M. A., and Joyce, E. M. (2009). IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr. Res. 107, 55–60. doi:10.1016/j.schres.2008.08.014.
44. Lewis, S., and Lieberman, J. (2008). CATIE and CUtLASS: can we handle the truth? Br. J. Psychiatry 192, 161–163. doi:10.1192/bjp.bp.107.037218.
45. Lezak, M. D., Howieson, D. B., Bigler, E. D., and Tranel, D. (2012). Neuropsychological Assessment. NewYork, NY: Oxford University Press.
46. Loh, S., Lamond, N., Dorrian, J., Roach, G., and Dawson, D. (2004). The validity of psychomotor vigilance tasks of less than 10-minute duration. Behav. Res. Methods Instrum. Comput. 36, 339–346. doi:10.3758/BF03195580.
47. Makara-Studziñska, M., Wołyniak, M., and Partyka, I. (2011). The quality of life in patients with schizophrenia in community mental health service-selected factors. J. Pre-Clin. Clin. Res. 5, 31–34. Available online at: http://jpccr.eu/fulltxt.php?ICID=978221.
48. Malla, A., and Payne, J. (2005). First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr. Bull. 31, 650–671. doi:10.1093/schbul/sbi031.
49. Marková, H., Laczó, J., Andel, R., Hort, J., and Vlček, K. (2015). Perspective taking abilities in amnestic mild cognitive impairment and Alzheimer’s disease. Behav. Brain Res. 281, 229–238. doi:10.1016/j.bbr.2014.12.033.
50. Mas-Expósito, L., Amador-Campos, J. A., Gómez-Benito, J., and Lalucat-Jo, L. (2011). The World Health Organization quality of life scale brief version: a validation study in patients with schizophrenia. Qual. Life Res. 20, 1079–1089. doi:10.1007/s11136-011-9847-1.
51. Matsui, M., Sumiyoshi, T., Arai, H., Higuchi, Y., and Kurachi, M. (2008). Cognitive functioning related to quality of life in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 280–287. doi:10.1016/j.pnpbp.2007.08.019.
52. Meltzer, H. Y., and McGurk, S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233–255. doi:10.1093/oxfordjournals.schbul.a033376.
53. Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., and Seidman, L. J. (2009). Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23, 315–336. doi:10.1037/a0014708.
54. Milev, P., Ho, B. C., Arndt, S., and Andreasen, N. C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 162, 495–506. doi:10.1176/appi.ajp.162.3.495.
55. Money, J., Walker, H. T., and Alexander, D. (1965). A Standardized Road-map Test of Direction Sense. Baltimore, MD: Johns Hopkins Press.
56. Narvaez, J. M., Twamley, E. W., McKibbin, C. L., Heaton, R. K., and Patterson, T. L. (2008). Subjective and objective quality of life in schizophrenia. Schizophr. Res. 98, 201–208. doi:10.1016/j.schres.2007.09.001.
57. Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., et al. (2008). The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165, 203–213. doi:10.1176/appi.ajp.2007.07010042.
58. O’Leary, D. S., Flaum, M., Kesler, M. L., Flashman, L. A., Arndt, S., and Andreasen, N. C. (2000). Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 12, 4–15. doi:10.1176/jnp.12.1.4.
59. Osterrieth, P. A. (1944). Le test de copie d’une figure complex: contribution a l’étude de la perception et de la memoir. Arch. Psychol. 30, 286–356.
60. Paradis, M. (2008). Bilingualism and neuropsychiatric disorders. J. Neurolinguistics 21, 199–230. doi:10.1016/j.jneuroling.2007.09.002.
61. PEBL (2012). The Psychology Experiment Building Language. Version 0.12, Test Battery 0.7. Michigan Technological University.
62. Peuskens, J., Demily, C., and Thibaut, F. (2005). Treatment of cognitive dysfunction in schizophrenia. Clin. Ther. 27(Suppl. A), S25–S37. doi:10.1016/j.clinthera.2005.07.015.
63. Peuskens, J., and Gorwood, P. (2012). How are we assessing functioning in schizophrenia? A need for a consensus approach. Eur. Psychiatry 27, 391–395. doi:10.1016/j.eurpsy.2011.02.013.
64. Piskulic, D., Olver, J. S., Norman, T. R., and Maruff, P. (2007). Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review. Psychiatry Res. 150, 111–121. doi:10.1016/j.psychres.2006.03.018.
65. Preiss, M., Bartoš, A., Čermáková, R., Nondek, M., Benešová, M., Rodriguez, M., et al. (2012). Neuropsychologická Baterie Psychiatrického Centra Praha. Praha: Psychiatrické centrum Praha.
66. Preiss, M., and Preiss, J. (2006). Test Cesty. Bratislava, MD: Psychodiagnostika.
67. Prouteau, A., Verdoux, H., Briand, C., Lesage, A., Lalonde, P., Nicole, L., et al. (2005). Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr. Res. 77, 343–353. doi:10.1016/j.schres.2005.03.001.
68. Rajji, T. K., and Mulsant, B. H. (2008). Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr. Res. 102, 122–140. doi:10.1016/j.schres.2008.03.015.
69. Reed, R. A., Harrow, M., Herbener, E. S., and Martin, E. M. (2002). Executive function in schizophrenia: is it linked to psychosis and poor life functioning? J. Nerv. Ment. Dis. 190, 725–732. doi:10.1097/00005053-200211000-00001.
70. Reitan, R. M., and Wolfson, D. (1985). The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tuscon, AZ: Neuropsychology Press.
71. Rey, A. (1964). L’examen Clinique en Psychologie. Paris: Presses Universitaries de France.
72. Ritsner, M. S. (2007). Predicting quality of life impairment in chronic schizophrenia from cognitive variables. Qual. Life Res. 16, 929–937. doi:10.1007/s11136-007-9195-3.
73. Rocca, P., Giugiario, M., Montemagni, C., Rigazzi, C., Rocca, G., and Bogetto, F. (2009). Quality of life and psychopathology during the course of schizophrenia. Compr. Psychiatry 50, 542–548. doi:10.1016/j.comppsych.2008.12.002.
74. Rodriguez, M. M. V. (2012). Feasibility of Non-Pharmacological Intervention in Therapy of Cognition Deficit in Czech Schizophrenia Patients-Computer-assisted Cognitive Remediation. Prague: Facutly of Arts Charles University.
75. Rossi, A., Mancini, F., Stratta, P., Mattei, P., Gismondi, R., Pozzi, F., et al. (1997). Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 95, 40–43. doi:10.1111/j.1600-0447.1997.tb00371.x.
76. Roy-Byrne, P., Dagadakis, C., Unutzer, J., and Ries, R. (1996). Evidence for limited validity of the revised global assessment of functioning scale. Psychiatr. Serv. 47, 864–866. doi:10.1176/ps.47.8.864.
77. Schultz, K. (1991). The Contribution of solution strategy to spatial performance. Can. J. Psychol. 45, 474–491. doi:10.1037/h0084301.
78. Spohn, H. E., and Strauss, M. E. (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98, 367–380. doi:10.1037/0021-843X.98.4.367.
79. Stirling, J., White, C., Lewis, S., Hopkins, R., Tantam, D., Huddy, A., et al. (2003). Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr. Res. 65, 75–86. doi:10.1016/S0920-9964(03)00014-8.
80. Stuve, T. A., Friedman, L., Jesberger, J. A., Gilmore, G. C., Strauss, M. E., and Meltzer, H. Y. (1997). The relationship between smooth pursuit performance, motion perception and sustained visual attention in patients with schizophrenia and normal controls. Psychol. Med. 27, 143–152. doi:10.1017/S0033291796004230.
81. Tzeng, D. S., Lung, F. W., and Chang, Y. Y. (2004). Comparison of quality of life for people with schizophrenia and mental health of caregivers beteen commn-based and hospital-based services. Kaohsiung. J. Med. Sci. 20, 443–451. doi:10.1016/S1607-551X(09)70183-4.
82. Vargas, M. L., Sanz, J. C., and Marín, J. J. (2009). Behavioral assessment of the dysexecutive syndrome battery (BADS) in schizophrenia: a pilot study in the Spanish population. Cogn. Behav. Neurol. 22, 95–100. doi:10.1097/WNN.0b013e318192cd08.
83. Ventura, J., Hellemann, G. S., Thames, A. D., Koellner, V., and Nuechterlein, K. H. (2009). Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 113, 189–199. doi:10.1016/j.schres.2009.03.035.
84. Wechsler, D. (1997). Manual for the Wechsler Memory Scale-III. San Antonio, TX: Psychological Corporation.
85. Weniger, G., and Irle, E. (2008). Allocentric memory impaired and egocentric memory intact as assessed by virtual reality in recent-onset schizophrenia. Schizophr. Res. 101, 201–209. doi:10.1016/j.schres.2008.01.011.
86. WHO group (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol. Med. 28, 551–558. doi:10.1017/S0033291798006667.
87. Wilson, B. A., Alderman, N., Burgess, P. W., Emslie, H., and Evans, J. J. (1996). Behavioural Assessment of the Dysexecutive Syndrome. London: Thames Valley Test Company.
88. Woods, S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64, 663–667. doi:10.4088/JCP.v64n0607.